15-18% of body weight 5 15-18% of body weight 6 14-17% of body weight 11-12.4% of body weight 10% of body weight 7 Weight Loss Injections and Medications Comparison Medication Zepbound (GLP-1 Tirzepatide) (GLP-1 Tirzepatide) Wegovy (GLP-1 Semaglutide) (GLP-1 Semaglutide) Saxenda (Liraglutide) (Liraglutide) Wegovy Pill (GLP-1 Semaglutide) (GLP-1 Semaglutide) Foundayo (orforglipron) (orforglipron) Qsymia (Phentermine & Topiramate) (Phentermine & Topiramate) What to Expect Zepbound Once weekly injection Wegovy Once weekly injection Saxenda Once daily injection Wegovy Pill One tablet daily Foundayo One tablet daily Qsymia One tablet daily Weight loss Zepbound 16-20% of body weight Wegovy 15-18% of body weight Saxenda 15-18% of body weight Wegovy Pill 14-17% of body weight Foundayo 11-12.4% of body weight Qsymia 10% of body weight How you lose weight Zepbound Reduce appetite, food intake, body fat and body weight Wegovy Increase satiety and control portions Saxenda Increase satiety and control portions Wegovy Pill Increase satiety and control portions Foundayo Slows digestion and reduces appetite Qsymia Suppress appetite and control cravings *Our board-certified doctors prescribe FDA-approved prescription GLP-1 medications and injections to people in NJ who meet the clinical qualifications
Dietary Effects on Drug Metabolism and Transport Robert Z Harris Graham R Jang Shirley Tsunoda Metabolic food-drug interactions occur when the consumption of a particular food modulates the activity of a drug-metabolising enzyme system, resulting in an alteration of the pharmacokinetics of drugs metabolised by that system
And plenty of time to connect as a team
For your prescribers reference, the pharmacy claims route through a dedicated BIN and PCN specific to the Bridge
1,2,3,4 The number of people with UC is estimated to be ~224 cases per 100,000 people per year globally, with an annual growth rate of 2%
Reference Novo Nordisk files for FDA approval of a higher dose of Wegovy injection 7.2 mg, Novo Nordisk, 26 November 2025, Higher-Dose Semaglutide Achieves Historic 21% Weight Loss in Landmark STEPUP Trial, Pharmacally, 16 October 2025,
